Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical...

Area of Science:

• Critical Care Medicine
• Pharmacology
• Nephrology

Background:

• Vasodilatory shock, often from sepsis, has high ICU mortality.
• Catecholamines, while first-line, cause severe adverse effects.
• Decatecholaminization using non-adrenergic vasopressors is a vital strategy.

Purpose of the Study:

• To review the role of vasopressin and its analogues (terlipressin, selepressin) in managing circulatory shock.
• To evaluate their physiological basis, clinical efficacy, and safety.
• To discuss their place in decatecholaminization therapy.

Main Methods:

• Comprehensive literature review of vasopressin system modulation in shock.
• Analysis of clinical trial data on vasopressin, terlipressin, and selepressin.
• Evaluation of physiological rationale and adverse event profiles.

Main Results:

• Vasopressin may not reduce overall mortality but significantly decreases renal replacement therapy needs.
• Terlipressin has a longer half-life but increased peripheral ischemia risk.
• Selepressin aims to mitigate edema but has not shown superior outcomes.
• Vasopressin agents are crucial for renal protection and reducing arrhythmias.

Conclusions:

• Modulating the vasopressin system is central to decatecholaminization in shock.
• These agents protect renal function and reduce catecholamine toxicity.
• Future research should focus on precision medicine and biomarkers for optimal therapy selection.